<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Alinezhad S</submitter><funding>FP7-PEOPLE (PRO-NEST)</funding><funding>NCI NIH HHS</funding><funding>Cancer Foundation Finland sr</funding><pagination>10</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4772680</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.&lt;h4>Methods&lt;/h4>AMACR and AR mRNA levels were measured with quantitative, reverse-transcription PCR (qRT-PCR) assays in 79 radical prostatectomy (RP) cases (including 69 benign (RP-Be) and 69 cancerous (RP-PCa) samples) and 19 beni</pubmed_abstract><journal>BMC urology</journal><pubmed_title>Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.</pubmed_title><pmcid>PMC4772680</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><funding_grant_id>238278</funding_grant_id><funding_grant_id>160065</funding_grant_id><funding_grant_id>140094</funding_grant_id><pubmed_authors>Taimen P</pubmed_authors><pubmed_authors>Alinezhad S</pubmed_authors><pubmed_authors>Bostrom PJ</pubmed_authors><pubmed_authors>Ochoa NT</pubmed_authors><pubmed_authors>Pettersson K</pubmed_authors><pubmed_authors>Vaananen RM</pubmed_authors><pubmed_authors>Bjartell A</pubmed_authors><pubmed_authors>Vertosick EA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.</name><description>&lt;h4>Background&lt;/h4>The high false negative rates for initial prostate biopsies refer a large number of the men for repeat biopsies each year. Therefore, biomarkers associated with high risk of the presence of malignancy in histologically benign biopsies could provide a tool to discriminate the patients who need repeat biopsy or intensive follow-up from those who do not. Here we examined the diagnostic applicability of alpha-methylacyl CoA racemase (AMACR) and androgen receptor (AR) mRNA expression and AMACR protein levels in benign and cancerous prostatic tissue.&lt;h4>Methods&lt;/h4>AMACR and AR mRNA levels were measured with quantitative, reverse-transcription PCR (qRT-PCR) assays in 79 radical prostatectomy (RP) cases (including 69 benign (RP-Be) and 69 cancerous (RP-PCa) samples) and 19 beni</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Feb</publication><modification>2025-04-04T11:02:52.352Z</modification><creation>2019-06-06T15:31:09Z</creation></dates><accession>S-EPMC4772680</accession><cross_references><pubmed>26928323</pubmed><doi>10.1186/s12894-016-0128-8</doi></cross_references></HashMap>